Mustafa Bilal Ozbay, Serhat Degirmen, Aysenur Gullu, Bede Nnaemeka Nriagu, Yasin Ozen, Ozlem Ozcan Celebi, Cagri Yayla
{"title":"Myval与当代经导管心脏瓣膜的比较结果:一项系统回顾和荟萃分析。","authors":"Mustafa Bilal Ozbay, Serhat Degirmen, Aysenur Gullu, Bede Nnaemeka Nriagu, Yasin Ozen, Ozlem Ozcan Celebi, Cagri Yayla","doi":"10.1007/s12928-025-01153-2","DOIUrl":null,"url":null,"abstract":"<p><p>Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45-0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01-1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative outcomes of Myval versus contemporary transcatheter heart valves: a systematic review and meta-analysis.\",\"authors\":\"Mustafa Bilal Ozbay, Serhat Degirmen, Aysenur Gullu, Bede Nnaemeka Nriagu, Yasin Ozen, Ozlem Ozcan Celebi, Cagri Yayla\",\"doi\":\"10.1007/s12928-025-01153-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45-0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01-1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.</p>\",\"PeriodicalId\":9439,\"journal\":{\"name\":\"Cardiovascular Intervention and Therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Intervention and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12928-025-01153-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-025-01153-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
经导管主动脉瓣置换术是严重主动脉瓣狭窄高危患者的关键干预措施。Myval,一种较新的经导管心脏瓣膜(THV),显示出希望,但缺乏与其他THV的全面比较。本研究比较了Myval与当代THVs的安全性和有效性。对涉及2335例患者的6项研究进行了系统回顾和荟萃分析。主要结局包括全因死亡率、心血管死亡率、新的永久性起搏器植入(PPI)、装置成功、早期安全性、急性肾损伤、中风、血管并发症和瓣膜反流。Myval与较低的PPI发生率相关(RR, 0.62;95% ci 0.45-0.86;P = 0.004),器械成功率较高(RR, 1.08;95% ci 1.01-1.16;P = .02),早期安全性(RR, 1.15;95% ci 1.05-1.27;P = .003)。在全因死亡率、心血管死亡率、急性肾损伤、中风、血管并发症和瓣膜反流方面,两组无显著差异。与当代thv相比,Myval可能在新的PPI、设备成功和早期安全性方面提供更好的短期结果。需要更大规模、更长期的前瞻性研究来证实这些发现。
Comparative outcomes of Myval versus contemporary transcatheter heart valves: a systematic review and meta-analysis.
Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45-0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01-1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.
期刊介绍:
Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.